MAZE
Maze Therapeutics, Inc.Company with tickers: MAZE
Market Cap
$1.57B
Shares Outstanding
55,345,261
CIK
1842295
CUSIP
578784100
Investor Relations
Investor relations
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Amy Bachrodt | Senior Vice President, Finance | Resigned | 2026-05-22 |